['carcinoma, non-small-cell lung']
['docetaxel', 'docetaxel', 'placebo', 'nintedanib']

        Inclusion criteria:

          -  Male or female patients of at least 18 years of age

          -  Histologically confirmed, adenocarcinoma of the lung, after failure of first line
             platinum-based chemotherapy.

        Exclusion criteria:

          -  More than one prior line of chemotherapy (i.e., 2nd or 3rd line chemotherapy) for
             advanced and/or metastatic (stage III B or IV NSCLC) or recurrent disease.

          -  Patients known to be positive for activating Epidermal Growth Factor Receptor (EGFR)
             mutation or anaplastic lymphoma kinase (ALK) translocation

          -  Previous therapy with other vascular endothelial growth factor (VEGF) or VEGFR
             inhibitors (other than bevacizumab) or docetaxel for the treatment of NSCLC at any
             time

          -  Prior monotherapy with an EGFR inhibitor except as maintenance therapy
      